Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 1, 2019

Tmunity raises funding to advance cancer-fighting cellular therapies

US-based Tmunity Therapeutics has raised a $75m Series B financing led by venture capital firm Andreessen Horowitz to propel next-generation T-cell therapies.

US-based Tmunity Therapeutics has raised a $75m Series B financing led by venture capital firm Andreessen Horowitz to propel next-generation T-cell therapies.

The financing also saw the participation of Westlake Village BioPartners, Gilead Sciences, The University of Pennsylvania, Be The Match BioTherapies and BrightEdge.

Tmunity plans to use the Series B proceeds to continue funding of ongoing and planned research, as well as clinical development of product candidates.

Additionally, the company will use the financing for the continued growth of its vertically-integrated viral vector and cell therapy product manufacturing and working capital, as well as other general purposes.

According to Tmunity, the company has raised $231m since inception.

Tmunity Therapeutics president and CEO Usman Oz Azam said: “We are fortunate to be funded by impressive investors who share our commitment to patients and our vision to dramatically change the way cancer is treated.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

“We see ourselves leading the innovation of the future of oncology treatment by uniting our foundational competencies in cell therapy with expertise in building new constructs, translating them and getting them into the clinic.”

Andreessen Horowitz general partner Jorge Conde will join the company’s Board of Directors as part of the Series B financing.

Conde said: “Tmunity’s founders Carl June and Bruce Levine invented CAR-T, one of the most profound breakthroughs against cancer in recent history.

“Together with Oz Azam, who with his team, brought the first CAR-T therapy to market, the company has built a pioneering platform that has produced an unrivalled therapeutic pipeline with programmes already in human clinical trials for both solid and liquid tumours.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU